A breakthrough medical innovation that began life at Stevenage Bioscience Catalyst has become the first non-hormonal menopause treatment in its class to be approved by the UK’s Medicines and ...

AbCellera Biologics (ABCL) marks a milestone, transitioning to clinical-stage biotech with ABCL635 dosing and pipeline expansion.

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

The extended review for Elinzanetant is supported by data from the Phase III OASIS 1, 2, and 3 trials, which supported the drug’s efficacy in the treatment of moderate to severe vasomotor symptoms due ...

The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

See disclosure here or remove ads. Bayer is expected to provide further clarity during its second-quarter earnings call on August 6. Analysts at Barclays continue to see elinzanetant as approvable and ...

Bayer announced that the US Food and Drug Administration (FDA) has notified the company that it has extended the review period for the New Drug Application (NDA) for elinzanetant, the first neurokinin ...